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The introduction of da Vinci Robotic Surgery to the ﬁeld of Gynecology has resulted in large changes in surgical management.
The robotic platform allows less experienced laparoscopic surgeons to perform more complex procedures. In general gynecology
and reproductive gynecology, the robot is being increasingly used for procedures such as hysterectomies, myomectomies, adnexal
surgery, and tubal anastomosis. Among urogynecology the robot is being utilized for sacrocolopexies. In the ﬁeld of gynecologic
oncology, the robot is being increasingly used for hysterectomies and lymphadenectomies in oncologic diseases. Despite the rapid
andwidespreadadoptionofroboticsurgeryingynecology,therearenorandomizedtrialscomparingitseﬃcacyandsafetytoother
traditional surgical approaches. Our aim is to update previously published reviews with a focus on only comparative observational
studies. We determined that, with the right amount of training and skill, along with appropriate patient selection, robotic
surgery can be highly advantageous. Patients will likely have less blood loss, less post-operative pain, faster recoveries, and fewer
complications compared to open surgery and potentially even laparoscopy. However, until larger, well-designed observational
studies or randomized control trials are completed which report long-term outcomes, we cannot deﬁnitively state the superiority
of robotic surgery over other surgical methods.
1.Background
Minimally invasive surgery (MIS) has revolutionized the
management of gynecologic disorders over the last 30 years.
However, the most substantial improvements have come
with the advent of robotic surgery. Initially, traditional
laparoscopy aﬀorded less invasive approaches to hysterec-
tomies, tubal ligations, adnexal surgery, and even lym-
phadenectomies and radical hysterectomies. However, not
all surgeons are comfortable with the laparoscopic approach
due to its steep and extended learning curve, nor are all
patientsandproceduresamenabletotraditionallaparoscopy.
In fact, the majority of advanced gynecologic surgeries are
still being performed through an abdominal incision. A
recent study looking at the rates of open versus vaginal or
laparoscopic hysterectomies from 2000 to 2005 at teaching
and nonteaching hospitals in Illinois revealed that teaching
hospitals were signiﬁcantly less likely to perform abdominal
hysterectomies (OR 0.69) after adjusting for confounding
variables, but the overall rates of abdominal hysterectomies
at teaching and nonteaching hospitals were still 82% and
77%, respectively [1]. Also, the rates of complications
from laparoscopic hysterectomies were less than the rates
from vaginal or abdominal hysterectomies. It has been well
established that laparoscopic surgery has several advantages
over abdominal surgery including shorter hospital stays,
faster recoveries, less blood loss, better cosmesis, and fewer
complications [2, 3].
However, there are several limitations to traditional
laparoscopy. The learning curve is very long, the hand
movements are counterintuitive, and the long instruments
working through a ﬁxed entry point cause small movements
and even tremors to be accentuated. These factors make
ﬁ n em o t o rc o n t r o lm o r ed i ﬃcult. Also, the instruments
have a limited range of motion and often require ergonom-
ically challenging positions. This can result in fatigue and
frustration by the surgeon during lengthy cases. Lastly, the
2-dimensional optics and the unstable camera platform
result in loss of depth perception and diﬃcult visualization,2 Obstetrics and Gynecology International
depending on the stability and skill of the assistant operating
the camera.
Due to these limitations, many complex surgical proce-
d u r e sa r es t i l ld o n ea sa no p e np r o c e d u r e .H o w e v e r ,w i t h
the advent of the da Vinci robotic system, (DRS) developed
by Intuitive Surgical, Sunnyvale, CA, USA and approved in
April 2005 by the United States Federal Drug Administration
(FDA) for gynecologic surgery, many surgeries that would
have been done with an abdominal incision are now being
performed with minimally invasive techniques utilizing the
DRS.
The term “robot” is derived from the Czech word
“robota” coined by the Czech playwright Karel Capek in
1921 in his play Rossum’s Universal Robots. Since then,
robots have become utilized in many industries, most
recently the medical ﬁeld. Initially, the concept of robotics
in medicine started with a simple voice-recognition system
called HERMES, which controlled the camera, light source,
insuﬄation, and table movements by voice commands.
In 1994, the FDA approved AESOP, a single robotic arm
that controlled the camera by voice command. In 1999,
two arms were added to create ZEUS, which introduced
the concept of the surgeon operating at a distance from
the patient at a console to control the robotic arms,
often referred to as telesurgery. In fact, in 2001, the ﬁrst
telesurgery was done by a surgeon in New York performing
a laparoscopic cholecystectomy on a patient in Strasbourg,
France [4]. These robotic platforms were initially funded
and developed by the Stanford Research Institute, the United
States Defense Department, and the National Aeronautics
and Space Administration in hopes to bring telesurgery
to wounded soldiers in the battleﬁeld. However, due to
limitations in telecommunication requirements, its use in
the battleﬁeld has not occurred, despite the technological
capabilities of the robotic platform. The robotic platform
was furthered developed and commercialized by Intuitive
Surgical Inc. to create the da Vinci robotic system (DRS).
The company then acquired the manufacturers of ZEUS and
phased it out of production and the ﬁrst successful surgery
using DRS was performed in Belgium in 1997 [5].
The da Vinci robotic platform consists of three compo-
nents: the surgeon’s console, which directs the movements of
the robotic arms, the vision system, and the patient-side cart,
which in the latest system has four arms. After placement of
port sites and docking the patient side cart, the surgeon sits
at the console and is able to view the pelvis through a three-
dimensional vision system in high deﬁnition. Furthermore,
the camera system is stabilized by the robotic platform and
easily controlled by the surgeon through foot pedals and
arm movements. At the console, the surgeon controls the
robotic arms and the EndoWrist instruments with natural
hand and wrist motions that mimic movements performed
in open surgery. In fact, the EndoWrist instruments are
designed with seven degrees of freedom, one more than
the human hand. Also, the robotic system is able to reduce
tremor and is ergonomic for the surgeon with armrests
and adjustable height and eye pieces. It also oﬀers ease of
use through foot pedals that control swapping in and out
the third robotic arm, moving and focusing the camera, and
controllingmonopolarandbipolarcurrentsconnectedtothe
EndoWrist instruments. All of these components reduce the
fatigue, frustration, and strain experienced by laparoscopic
surgeons during long or diﬃcult cases.
Due to such advancements, the robotic platform allows
less experienced laparoscopic surgeons to perform more
complex procedures. The surgeon is able to progress quickly
along the learning curve and accomplish tasks such as
intracorporeal suturing and knot tying, ureterolysis, lym-
phadenectomies, and lysis of dense adhesions with ease and
improved visualization. Also, additional assistance can be
achieved through the 10–15mm assistant port to provide
suctioning, retraction, vessel coaptation, passage of suture
or laparotomy sponges, and even thrombogenic agents as
needed. Furthermore, uterine manipulation by an assistant
providesanothermethodtoimprovevisualizationandaccess
to the pelvis, which is unique to gynecologic surgery. Also,
after completion of a total hysterectomy, the vaginal canal
oﬀers access to the pelvis for the removal of specimens.
Many gynecologic surgeons now are performing proce-
dures that they never would have been comfortable perform-
ing with traditional laparoscopy, aﬀording many patients the
option of minimally invasive surgery (MIS). The adoption
of the robot has come into play in general gynecology as
well as in nearly every subspecialty of gynecology. In general
gynecology and reproductive gynecology, the robot is being
increasingly used for procedures such as hysterectomies,
myomectomies, adnexal surgery, and tubal anastomosis.
Also, among urogynecology, the robot has been utilized for
sacrocolpopexies and ﬁstula repairs. But perhaps the most
profound utilization of the robot has been in the ﬁeld of
gynecologic oncology, where the robot is being increasingly
used to perform hysterectomies and lymphadenectomies
for endometrial cancer staging, radical hysterectomies and
trachelectomies for cervical cancer, and even for the staging
and debulking of early ovarian cancer.
For example, at one major university hospital center, the
route of hysterectomy changed signiﬁcantly after the intro-
duction of robotic surgery. The rate of open hysterectomies
declined (52% to 43%), the rate of traditional laparoscopic
hysterectomies decreased (18% to 8%) as well as the rate
of vaginal hysterectomies (27% to 24%) while the rate of
robotic hysterectomies increased from 2.5% to 25% [6].
Also, at another large academic teaching hospital, after
the introduction of robotics, the proportion of cases done
through minimally invasive surgery increased from 9% to
36% in the third year after introducing the robot [7].
Despite the rapid and widespread adoption of DRS in
gynecology, there are no randomized trials comparing its
eﬃcacy and safety to other traditional surgical approaches.
In fact, the vast majority of the published literature on
DRS in gynecology consists of case reports, descriptions of
technique, and retrospective case series, and several review
articles summarize these publications [8–13]. There was a
recent systematic review and meta-analysis comparing the
eﬃcacy of DRS to open surgery (OS) and laparoscopy (LSC),
but the ﬁrst publication only included literature related
to general surgery [14]. However, a second publication by
the same group has recently reported a meta-analysis ofObstetrics and Gynecology International 3
observational studies in robotic gynecologic surgery that
included studies published up until October, 2009 [15].
Our aim is to update this previously published review.
We will focus on comparative observational studies only,
understanding the inherent limitations of observational
studies due to confounding and bias, and the potential
for time-period eﬀects when historical controls are used.
Also, there is vast heterogeneity in the studies reported
due to diﬀerences in institutional practices, surgeons, and
their skills as well as their place on the learning curve, and
patient populations. Taking these limitations into account,
we will objectively and systematically review the current
evidence describing the safety and eﬃcacy of DRS in
benign and malignant gynecologic disease compared to open
surgery (OS) or laparoscopy (LSC). We will evaluate only
comparative observational studies in which one type of
gynecologicprocedureisperformedamongallsubjectsbeing
compared. Due to the anticipated heterogeneity between the
studies and high likelihood of biased estimates, we will not
report overall measures of eﬀect. This note of caution was
described in the 2nd of “Systematic Reviews In Health Care:
Meta-analysis in context.”
Due to the eﬀects of confounding and bias, such
observational studies may produce estimates of
associations that deviate from the underlying
eﬀect in ways that may systematically diﬀer
from chance. Combining a set of epidemiolog-
ical studies will thus often provide spuriously
precise, but biased, estimates of associations.
The thorough consideration of heterogeneity
between observational study results, in particu-
lar of possible sources of confounding and bias,
will generally provide more insights than the
mechanistic calculation of an overall measure of
eﬀect [16].
Nonetheless, we predict that DRS will have equal out-
comes compared to LSC and improved outcomes compared
to OS, with no increased safety concerns across the majority
of gynecologic procedures. We anticipate a paucity of data
concerninglong-term outcomes,limiting our ability to make
recommendations regarding the utility of DRS in regards to
particular gynecologic conditions.
2. Methods
On June 8th, 2011, relevant articles were identiﬁed through
a Medline/pubmed search using the keywords from Title/
Abstract ﬁelds: Robot∗ OR Davinci OR da Vinci AND either
Gynecolog∗ OR Hysterectomy OR Myomectomy OR tubal
OR adnexal OR ovar∗ OR sacrocolpopexy OR Endometrial
cancer OR Uterine cancer OR cervical cancer OR cervix OR
ovarian cancer, from 1990 to June 8th, 2011. The search was
limited to English language and published studies only. A
manual inspection was also made of the references cited in
the articles found. Articles were identiﬁed by their title, and,
among all relevant articles, the abstracts were reviewed and
full text when necessary.
We included studies that reported on perioperative
outcomesofagroupthatunderwentDRScomparedtoeither
historical or concurrent controls, matched or unmatched,
that had similar procedures performed but underwent
LSC and/or OS. Primary outcome data abstracted includes
perioperativedatasuchasoperatingtime,bloodloss,lymph-
node count when applicable, and length of hospital stay
as well as rate of blood transfusion, any intraoperative
or postoperative complications, and conversions to open
surgery. When short- or long-term clinical outcome data was
reported, it was also collected. Demographic data such as
age,bodymassindex(BMI),surgicalindications,anduterine
weight were also abstracted when appropriate.
We excluded studies if the subjects were nonhuman, if
there was no control group, if the groups being compared
appeared signiﬁcantly diﬀerent from one another, if the total
number of cases in the DRS group was less than 20 to
minimize potential learning curve biases, or if the study
methodology appeared ﬂawed or was not well described.
Also, quality of the studies were assessed, and if we felt
they did not clearly deﬁne the question, lacked appropriate
followup of the patients, or had dramatic inequalities in
patient management between the groups, the study was
excluded.
Meta-analysis of observation studies in Epidemiology
reporting guidelines was followed when conducting this
study [17]. Information abstracted from each identiﬁed
study was tabulated in a collection form for subsequent
reference and analysis.
3. Results
A total of 665 studies were identiﬁed, of which 434 were
foundtobeunique.Fromthese434studies,45metinclusion
criteria and upon further review 13 of these studies met
exclusion criteria. One of these studies that met exclusion
criteria (n<20) was still included due to its superior
design and novel ﬁndings [18]. The remaining 12 studies
were excluded for sample size less than 20 (10), a variety
of procedures among groups (1), and questionable balance
between groups as well as methodology of study (1). The
remaining 33 studies were then included in this systematic
review, and their outcomes are summarized in tabulated
form.
4. Benign andReproductive
Gynecologic Surgery
4.1. Tubal Anastomosis. The ﬁrst reports of the da Vinci
robot were in urologic procedures in 1995 and cardiac
procedures in 2001 [19, 20]. In 2000, the ﬁrst case of robotic
surgery in gynecology was reported, a tubal anastomosis
(TA) [21]. To date, two studies describe robotic compared to
other approaches in performing TA [22, 23]. Unfortunately,
both these studies meet exclusion criteria (n<20), but,
due to the paucity of data and novelty of their data,
we will discuss them for informative purposes. The ﬁrst
study conducted by Goldberg and Falcone at the Cleveland4 Obstetrics and Gynecology International
clinic includes the ﬁrst ever performed case in addition to
their subsequent 9 patients that underwent TA robotically
with ZEUS compared to their subsequent 15 patients that
underwent LSC TA. Due to the small number of subjects
(n = 10 in the robotic group) and noncomparability of
groups (women in the LSC group were signiﬁcantly older
and tended towards having larger BMI and prior surgeries),
this study has many potential biases. In addition, 6 of the 15
patients in the LSC group were lost to followup. Also, the
robotic group excluded patients with other infertility factors,
but the LSC group included 8 patients with other infertility
factors.Nonetheless,theyreportedhighertubalpatencyrates
(90% versus 69%) and pregnancy rates (50% versus 38%)—
after adjusting for loss of followup and excluding those with
other infertility factors—in the robotic group compared to
the LSC group, but these diﬀerences were nonsigniﬁcant.
There were signiﬁcantly longer operating room times and
estimated blood loss (EBL) in the robotic group of 124
minutes and 50mL, respectively, compared to LSC TA.
The second study evaluated 18 patients that underwent
DRS for TA compared to 10 historic controls (HC) who
underwent OS for TA one year prior [23]. The same surgeon
performed every one of these cases, and the investigators
excluded other infertility factors between both groups. They
measured operative times, hospitalization time, charges,
complications, postoperative recovery, postoperative tubal
patency, and clinical outcomes. Demographic data as well as
mean time from sterilization were comparable between the
groups. Statistically signiﬁcant diﬀerences included longer
operative times in DRS versus OS of 201 min versus 155min;
however, the console time was only 156min, comparable to
the operative times in the OS group. Patients in the DRS
group were all discharged within 4 hours postoperatively;
whereas, in the OS group the average length of hospital
stay postoperatively was 35 hours. There was only one
complication, a trocar injury to the inferior epigastric artery
in the DRS group, which was recognized and cauterized
intraoperatively. There were no conversions to OS. Also,
analgesia use was less, and time to return to activities of daily
living(ADL)wasfasterintheDRSgroup(11versus28days).
Clinical outcomes were not diﬀerent although the followup
was shorter for patients in the DRS group versus OS group.
Lastly, they found that DRS TA was cost eﬀective in terms
of cost per live birth as compared to OS. Increased cost was
balancedbyincreasedrecoverytimesandhospitalstaysinthe
OS group [23].
4.1.1. Recommendations: Level 2− Grade D. Although these
studies both have potential for bias, they do suggest that even
at the beginning of their learning curve, DRS for TA does
appear to have advantages in terms of faster recoveries over
OSandatleastequaloutcomescomparedtoLSC,butfurther
studies and randomized trials are warranted to compare
eﬃcacy and safety of DRS in TA.
4.2. Adnexal Surgery and Endometriosis Treatment. Most
of the literature concerning adnexal surgery is not well
characterized as many of the reported adnexal procedures
are done concurrently with hysterectomies. Often, isolated
oophorectomies or cystectomies are easily accomplished
with traditional laparoscopy as initially described in 1979
[34]. However, cases in which adhesive disease, advanced
endometriosis, or large-complex masses are present, the use
of robotics may make completion of the desired procedure
more feasible without necessitating converting to OS. Nezhat
et al. reported, in 1999, the diﬀerence in operative times
for hysterectomies with (n = 17) and without BSO
(n = 10) equaling an additional 99 minutes [35]. Also,
in an earlier series by the same group, they described
utilizing the robot to treat endometriosis in two patients,
which entailed resection of endometriotic lesions, lysis of
adhesions, ovarian cystectomy, and repair of the ovary after
cystectomy. Neither patient required a conversion to open
orexperiencedintraoperativeorpostoperativecomplications
[36]. Liu et al. also reported a successful case of a partial
bladder resection due to inﬁltrating endometriosis using
DRS [37]. At the same time, Chammas et al. also reported
a case of endometriosis managed with DRS that included
surgical resection of a bladder mass and rectal nodule as well
as excision of an ovarian cysts and resection of peritoneal
endometriotic implants [38].
The initial report of the feasibility and eﬃcacy of LSC
adnexectomy over OS was completed in 1994 by Pittaway
et al. [39]. This report was a retrospective case-control
study using historic controls (HCs). They reported that
LSC had improved operative times, blood loss, hospital stay,
recovery time, and costs, with no diﬀerence in complications
or clinical outcomes. Most adnexal surgery is now done
laparoscopically. Since the introduction of DRS, the only
study comparing outcomes of LSC to DRS in adnexectomy
was published in 2009 by Magrina et al. [24]. They evaluated
85 patients that underwent DRS adnexectomy compared
to 91 patients that had LSC adnexectomy during the same
time period, concurrent controls (CCs), and by the same
surgeons (SSs). The only diﬀerence between the groups was
that women in the DRS group had higher BMIs and higher
anesthetic risk class. This diﬀerence may account for the
increased median OR time in the DRS group (77 versus 62).
However, among patient with BMI over 30, there was no
diﬀerence in median OR time in the DRS group (66 versus
58). Also, although overall blood loss was not diﬀerent,
among a subset of women with BMI over 30 DRS had less
blood loss compared to LSC. Otherwise complication rates
andhospitalstayswereequivalentwithnobloodtransfusions
or conversions (Table 1).
4.2.1. Recommendation: Level 2+ Grade D. The advantage of
DRS for adnexectomy likely lies among a subgroup of obese
women where a diﬃcult dissection is anticipated.
4.3. Myomectomy. Myomectomy remains the gold standard
for surgical treatment of women with symptomatic myomas
that desire future fertility. While many adnexal surgeries can
be performed with traditional laparoscopy, myomectomies
are often more technically challenging, and the vast majorityObstetrics and Gynecology International 5
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are still performed by OS despite the introduction of laparo-
scopicmyomectomiesbySemmin1979[34]andthebeneﬁts
of OS substantiated by a prospective randomized controlled
trial in 2000 with pregnancy as the primary outcome [40].
TheunderutilizationofLSCmyomectomyislikelyduetothe
extensive suturing of the myoma bed and uterine serosa as
well as the precise dissection and torque required to remove
the myoma. Additionally, the risk of uterine rupture during
pregnancy after LSC myomectomy has been reported as 1
percent. Due to such risk, only skilled LSC surgeons should
perform this procedure. However, robotic surgery, with its
ease of suturing, knot tying, and improved visualization,
aﬀords the option of a minimally invasive approach to
myomectomies among less advanced laparoscopic surgeons.
There have been several observational studies [35, 36,
41, 42]a n dc a s er e p o r t s[ 43, 44] describing the feasibility,
complications, and success of DRS myomectomies. Among
theses studies, only the case series of 35 patients reported
conversions to OS (2/35) [41]. To date, there have been ﬁve
comparative observational studies of DRS for myomectomy
(Table 1).
The ﬁrst study was published by Advincula et al. in
2007 [25]. They performed a retrospective case-matched
study on a total of 58 patients that had DRS or OS for
myomectomy in 2000 to 2004. One surgeon performed all
the DRS cases and six diﬀerent surgeons performed the
OS cases. They were matched on myoma weight, age, and
BMI. They found that the DRS had less EBL, a shorter
length of hospital stay, and fewer complications, but longer
operating times and larger hospital costs with no diﬀerence
in professional reimbursement. Recently, Ascher-Walsh and
Capes have compared 75 cases of DRS myomectomy to 50
HCs of OS myomectomy [27]. They only included patients
with 3 or less myomas and uterine size 20 weeks or less. The
groups were comparable and they found longer operative
timesforDRSbutlessEBL,shorterhospitalstays,andafaster
return to normal diet. There was also signiﬁcantly less febrile
morbidity with DRS compared to OS. They also concluded
that DRS for myomectomy is superior.
T h eﬁ r s ts t u d yo fD R Sc o m p a r e dt oL S Cf o rm y o m e c -
tomies was done by Nezhat et al. in 2009 [18]. They
compared 15 DRS to 35 LSC myomectomies. All cases were
performed by the same surgeon (C.N.) and during the same
time period. The patients were matched by age, BMI, parity,
previous abdominal surgeries, size, number, and location of
myoma. Although this study has n<20 for the DRS group,
due to its excellent design (matched concurrent controls
with the same surgeon), we included their results in our
systematic review. They reported increased operative times
in the DRS group but otherwise equal EBL, hospital stay, and
pregnancy outcomes. However, the additional cost (hospital
charge) of DRS versus LSC was $21,500. They therefore
concluded that there are no signiﬁcant advantages of DRS
compared to LSC and that the role of the DRS may be
better reserved for surgeons at the start of their learning
curve. Bedient et al. in 2009 performed a comparable
study with similar short-term outcomes after adjusting for
diﬀerences in uterine size, number of ﬁbroids, and size of
largest ﬁbroid using a multivariate regression model [26].
Despite the equivalence of their results, they did conjecture
that robotic surgery improved ﬁbroid enucleation, layered
closure and also lowered the number of uterine incisions
potentially protecting against the risk of uterine rupture
in subsequent pregnancies. They also noted that important
long-term outcomes were not assessable due to their short
followup, similar to the majority of the other studies.
The largest and most recent study to date by Barakat et
al., compared DRS to LSC and OS [45]. Historic controls
were used in this study over an extended time period from
1998 to 2008. There was no mention of the surgeons who
performed the surgeries or where they were performed.
Also, the groups were fairly comparable, except that in
the LSC group patients had smaller and lighter myomas
and patients in the OS group had higher BMIs and more
previous LSC surgeries. In this study, LSC was more often
used for patients with smaller myomas, while DRS allowed
performance of myomectomy in patients similar to those
in the OS group. Nonetheless, they found longer operative
times in the DRS group compared to OS but also shorter
hospital stays and fewer complications. Similarly to previous
studies, DRS was comparable to LSC in terms of blood
loss, operative time, and hospital stay. However, there were
more complications (two blood transfusions and one bowel
injury) in the LSC group compared to no complications in
the DRS group. Yet, due to the historic nature of the controls
and potential diﬀerence in surgeons, it is diﬃcult to attribute
thesediﬀerencesincomplicationstotheuseofLSCoverDRS
alone. However, LSC and DRS had a signiﬁcantly decreased
rate of blood transfusions compared to DRS [45].
4.3.1. Recommendations: Level 2+ Grade C. All of these
studies suggest that DRS is equivalent to LSC myomectomy,
but likely only in the hands of experienced LSC surgeons.
However, DRS may be superior to LSC for patients with
large or multiple myomas who traditionally would not be
considered candidates for MIS. Therefore, either among
less experienced laparoscopic surgeons or among patients
predicted to have diﬃcult myomectomies DRS may be
preferable over LSC. On the other hand, DRS appears
to be superior to OS although no studies to date have
looked at long-term outcomes. The risk of uterine rupture
could theoretically be increased with DRS compared to OS.
Therefore, until long-term data are available we hesitate to
advise routine DRS myomectomies over OS.
4.4. Hysterectomy. Hysterectomies are the most common
nonpregnancy-related procedure among women with over
600,000 performed annually in the United States, and
90% are for benign conditions [46, 47]. In the past, the
only two options for performing a hysterectomy were an
abdominal approach or a vaginal approach. However, in
1989, laparoscopy was ﬁrst used to perform a hysterectomy
[48]. It wasn’t until over a decade later, in 2002, that the use
of the da Vinci robot for hysterectomies was ﬁrst reported
[49] .T h ei n v e s t i g a t o r sc o n d u c t e dar e t r o s p e c t i v ec a s er e v i e w
of 11 patients with a variety of indications for simple
hysterectomy including benign and malignant processes,8 Obstetrics and Gynecology International
with one patient undergoing a staging procedure for ovarian
cancer. Their operating times varied from 270 to 600min.
with an average EBL of 300mL (range, 50 to 1500mL). The
average hospital stay was 2 days (range, 1–3days). There
were no conversions to open surgery; however, one patient
experienced bleeding from an infundibulopelvic ligament
requiringminilaparatomyandoneunitofbloodtransfusion.
Then, Marchal et al. in 2005 reported on 30 cases done
in Belgium and France for malignant and benign diseases
[50]. They reported shorter operating times of 166min.
for benign cases and 181min. for malignant cases with an
average EBL of 83mL. They did not have any intraoperative
complications, but one conversion to open due to body
habitus and a 17% postoperative complication rate. Beste et
al. in 2005 reported a case series of 10 patients undergoing
hysterectomy for benign conditions and showed operative
times of 148min to 277min with an EBL of 25 to 350mL
and hospital stay averaging one day. Initially, they intended
to treat 11 patients with a robotic approach, but one was
converted to an open procedure in order to control bleeding
during skeletonizing of the uterine vessels. Also, one patient
had a cystotomy, but otherwise no other complications.
Many other similar retrospective case series have reported a
variety of diﬀerent outcomes and complication rates [35, 42,
51–54].
Lenihan et al. in 2008 prospectively evaluated 113
consecutive gynecologic cases performed robotically, 91 of
which were hysterectomies for benign conditions [55]. Two
surgeons performed all the cases after undergoing computer-
based and porcine laboratory training, and their learning
curves were assessed. Robotic console and operative times
plateaued after approximately 50 cases at 50min. for console
time and 90min. for total operative time. While total
operating times and EBL were aﬀected by uterine weight,
robot console time was not signiﬁcantly aﬀected by uterine
weight. However, the time increased on average only 10min.
among cases with larger uteri, which was due to morcellation
and removal of the uterus. Also, the EBL decreased from
160mL in the ﬁrst 25 cases to only 50mL in cases 76–
100. There were no conversions to open, and only twice did
they convert to a laparoscopic assisted vaginal hysterectomy
(LAVH) to facilitate removal of the uterus. They did report
4 complications including a delayed ureteral injury near the
cuﬀ,a6 - w e e kc u ﬀ dehiscence, a post-operative fever, and a
vaginal laceration from the removal of the uterus [55].
Bell et al. in 2009 also reported on the learning curve
among 100 robotic hysterectomies performed by a single
surgeon [56]. They collected operative times and compli-
cations retrospectively and found that the total operating
time declined as case number increased with the times in
the ﬁrst, second, third, fourth, and ﬁfth quintiles being 124,
94, 85, 88, and 81 minutes. Also, the rates of complications
were highest in the ﬁrst 20 cases (15%), but only 5% for
the remaining cases. Therefore, they concluded that the
maximum improvement in surgical times occurred after
only 20 cases [56], contrary to 50 cases as reported by
Lenihanet al.[55].Despitetheshortlearningcurves,thevast
majority of minimally invasive hysterectomies in the United
States, 95%, are being performed LSC without robotic
assistance [57].
While there are many studies as mentioned above which
are reporting outcomes of DRS for hysterectomies in benign
disease,thereareonly4studiestodatereportingcomparative
observational data of DRS versus LSC hysterectomy. No
studies compare DRS to OS for hysterectomy. Payne and
Dauterive reported the ﬁrst study in 2008. They retro-
spectively reviewed 200 cases of consecutive hysterectomies
completed before and after the implementation of a robotics
program at their institution with the ﬁrst 100 cases intended
to be performed by LSC and the second 100 cases intended
to be performed by DRS [29]. All the hysterectomies were
done for benign conditions, and the mean uterine weights
and body mass index (BMI) did not diﬀer between the
two groups. The overall operative time was longer in the
LSC group (120 versus 92min.), but, when comparing the
operative times of the last 25 DRS cases to the LSC cases,
the DRS cases were signiﬁcantly shorter (79 versus 92 min.).
Also, the average EBL of the DRS cases were half that of
the laparoscopic cases (61 versus 113mL) and the patients
hadshorterhospitalstays(1versus1.6days).Twenty-percent
of the intended LSC cases were done as an exploratory
laparotomy or converted to OS (eleven for large uterine
size, 8 due to adhesions, and one case due to a tuboovarian
abscess) while only 4% of the DRS cases were converted to
OS (one due to a cystotomy, and 3 due to large uterine size).
There was one enterotomy and one vaginal tear in the LSC
group and one cystotomy and one cuﬀ infection in the DRS
group. Thus, the robotic group had improved outcomes with
no diﬀerence in complication rates [29].
Although not a comparative study, Payne et al. have
recently reported on a multicenter retrospective case series
of DRS hysterectomies performed on uteri of at least 250g.
[58]. The reported only 4 conversions to OS among 256
cases (1.6%) with a minor complication rate of 1.6% and
a major complication rate of 2.0%. Interestingly, three of
the four patients with conversion to OS had uterine weights
above 1,000g. Uterine weight above 500g was independently
associated with increased EBL and operative times in mul-
tivariable linear regression models with approximately 40
additional minutes of operative time and 60mL increased
blood loss [58]. This study highlights the utility and safety
of robotic hysterectomies for large uteri; however, careful
consideration should be made for those with extremely large
uteri.
Shashoua et al. in 2009 compared 24 patients that
underwent DRS hysterectomy versus 44 patients that under-
went LSC hysterectomy [30]. Of note, one patient in
each group underwent a simple hysterectomy due to a
malignant process. They found that DRS was associated with
a signiﬁcantly shorter hospital stay, a decrease in narcotic
use postoperatively, but a longer operative time compared
to LSC. However, there was no diﬀerence in EBL or drop in
hemoglobin. Although DRShad an increased operative time,
patients in the DRS group tended to have larger uteri, and a
signiﬁcantlylargerproportionunderwentmorcellation(23%
versus 2%). In fact, in a multivariate analysis, only need forObstetrics and Gynecology International 9
morcellation, uterine weight, and BMI were independently
associated with increased operative times, and not utilization
ofDRS.Also,therewerenoconversionstoOSineithergroup
and the rates of complications were comparable.
Sarlos et al. in Switzerland have recently published a
prospective observational study of 40 patients undergoing
DRS hysterectomy with uteri <500g. compared to 150
matched (surgeon, age, BMI, uterine size) HCs [31]. They
found that DRS had signiﬁcantly longer operative times, but
no diﬀerence in blood loss, hospital stay, or complication
rates. They also evaluated costs of the two procedures and
found DRS cost 1,916 more Euros than LSC hysterectomy.
Therefore, they concluded that while DRS is a feasible and
an interesting new technique with comparable outcomes
to LSC, they hesitated to promote its adoption for benign
hysterectomies due to concerns of cost until randomized
trials were conducted to clearly elucidate its potential
beneﬁts.
Giep et al. compared 237 DRS hysterectomies performed
by 2 surgeons in a community hospital to 265 LSC-assisted
vaginal hysterectomies (LAVHs) performed by the same 2
surgeons and 9 of their partners [32]. Although the DRS
group had more complexity (prior abdominal surgeries and
more procedures for endometriosis and pelvic reconstruc-
tion) as well as greater uterine weights, DRS still had shorter
operative times, EBL, and length of hospital stay. They
also reported similar complication and conversion rates.
However,theywereonlyabletoassesscomplicationspostop-
eratively after discharge in the DRS group, not in the LAVH
group. This reporting bias favors the LAVH group, making
the ﬁnal statement of equivalence in complication rates pre-
sumptively stronger in favor of DRS. Furthermore, through
multivariate regression analysis, only LAVH, obesity, older
age, and uterine weight >250g were independently associ-
ated with longer operative times. They conclude that DRS is
advantageous over LSC hysterectomy, speciﬁcally LAVH.
Another study by Pasic et al. utilized the Premier hospital
database, which contains complete patient billing, hospital
costs, and coding histories of more than 600 health care
centers in the U.S [57]. They identiﬁed 36,188 patients
that had MIS hysterectomies, with slightly less than 5% of
these patients undergoing DRS and only 13% of the 358
hospitals identiﬁed had access to the DRS. While they did
obtain information on patients’ comorbid conditions, there
was no mention of the patients’ uterine weights, BMI, or
history of prior surgeries. Also, there were a large variety
of procedures performed including radical hysterectomies
for malignancies, lymphadenectomies, supracervical hys-
terectomies, and the vast majority of the procedures were
LAVH. They did control for surgery types, indications for
surgery, region, hospital type, comorbid illnesses, and age in
multivariateregressionanalysistoassesstheeﬀectsofrobotic
or no robotic assistance on hospital costs, and surgery
time, and length of stay. However, due to the heterogeneity
of their patients, procedures, and surgeons, and because
identiﬁcation of complications could only be completed
through reported ICD-9 codes, this study was excluded.
Nonetheless, they found similar adverse events across DRS
and LSC hysterectomies, but signiﬁcantly longer surgical
times with DRS and shorter lengths of stay. However, due to
higher costs of DRS, they cautioned against its routine use in
LSC hysterectomies [57].
4.4.1. Recommendations: Level 2+ Grade C. DRS may oﬀer
improved recovery, less blood loss, and decreased conversion
ra t e st oO Sc o m p a r e dt oL S C .D R Sm a yt a k el o n g e rt h a nL S C
hysterectomies, but this most likely occurs at the onset of the
learningcurveandismostlikelyattributabletolargeruterine
weights and patient BMIs, rather than surgical approach.
Therefore, DRS for simple hysterectomies for benign design
is most likely the preferred modality for less experienced
laparoscopic surgeon or for patients with larger uterine
size or anticipated diﬃcult surgeries that would require
converting to OS.
5.UrogynecologicSurgery
5.1. Sacrocolpopexy. Approximately 200,000 women in the
US annually undergo surgery for vaginal vault prolapse, and
30% of these women will require reoperation for recurrent
prolapsed [59, 60]. Abdominal sacrocolpopexy has emerged
as the gold standard treatment for recurrent prolapse with a
90% success rate at 5 years [61]. While recent studies have
shown comparable outcomes with LSC sacrocolpopexy [2],
due to the limitations of LSC and the suturing required
during sacrocolpopexy, many less experienced LSC surgeons
have begun utilizing the DRS. The ﬁrst case series of
DRS sacrocolpopexy involved 5 patients at Mayo Clinic
in the Department of Urology, and they later included
another 15 patients in a subsequent publication [62, 63].
They also subsequently reported long-term outcomes on
theses patients with an average followup of 24 months and
among 21 patients, there were one recurrent rectocele, one
recurrent vault prolapse, and two mesh erosions (thought
to be due to overly aggressive bladder dissections done in
earlier cases) [64]. The Cleveland Clinic also reported a
case series of 15 patients undergoing DRS sacrocolpopexy or
hysteroscacrocolpopexy and reported mean operative times
of 317 minutes, EBL of 81mL, and an average hospital stay
of 2.4 days. They also reported three conversions: to LSC,
vaginal, or OS due to bowel adhesions. They only had one
complication, a bowel serosa tear, and they reported mean
preoperative and postoperative POP-Q stages of 3.1 and 0.
Although they concluded that DRS oﬀered a shorter learning
curve than LSC and provided durability equal to OS with
decreased morbidity, they did note that the loss of haptic
feedback with DRS made placement of vaginal and sacral
sutures more diﬃcult [65].
To date, there are only two reports of observational data
comparing DRS, LSC, and OS in performing sacrocolpopex-
ies [33, 66]. The later report comparing DRS to LSC was
excluded due to less than 20 DRS surgeries in the treatment
group. Nonetheless, they did report longer operative times
in the DRS group compared to LSC sacrocolpopexies and
shorter hospital stays among DRS with equivalent rates
of complications. They also reported clinical outcomes at10 Obstetrics and Gynecology International
an average of 29 months followup and found similar objec-
tive cure rates of 93% and 91% with 1 recurrent prolapse
(≥stage II) in the DRS group versus 2 recurrent prolapses
(≥stage II) in the LSC group. Also, there were no mesh
e x p o s u r e so re r o s i o n s[ 66]. The ﬁrst report, however, by
Gelleretal.in2008meetsalltheinclusioncriteria [33].Itisa
retrospective review of 73 DRS sacrocolpopexies performed
by one surgeon versus 105 OS sacrocolpopexies performed
by another surgeon at the same institution. Although the
patients were similar in age, race, and BMI, patients in
the DRS group had more signiﬁcant prolapse based on
their preoperative POP-Q scores and were also more likely
to undergo hysterectomy and less likely to undergo other
concomitant procedures for prolapse. Among the DRS
group, they reported longer operative times, less EBL, and
shorter hospital stays. Due to the diﬀerences in concomitant
procedures, they performed multivariate adjusted analyses
to control hysterectomy, concomitant procedures, as well
as lysis of adhesions and BMI and still found signiﬁcantly
longer operative times and less EBL in the DRS group. They
had one conversion to OS due to extensive adhesions and a
cystotomy in each group that was repaired intraoperatively
without complications or conversions. There was one pul-
monary embolism in the DRS group, but otherwise rates of
complications were equivalent. They also reported equal 6-
month post-operative POP-Q points between the DRS and
OS groups, except for a signiﬁcant improvement in the C
point POP-Q among patients that underwent DRS (P =
0.008). This ﬁgure is impressive considering that patients
in the DRS group had signiﬁcantly worse C point scores
preoperatively compared to patients that underwent OS.
Their results are encouraging for DRS, but they should be
cautioned because of their lack of long-term followup [33].
The DRS is also used for other urogynecologic proce-
d u r e ss u c ha sﬁ s t u l ar e p a i r s ,b u to n l yc a s er e p o r t s[ 67]a n d
case series have been reported to date [68–70]. All of these
reports show success with DRS and no complications. There
has also been a case report of DRS sigmoid vaginoplasty in
a 17 year-old 46 XY adolescent that took 9 hours and 45
minutes to complete with no complications and successful
dilation at 10-month followup [71]. Thus, DRS appears to
have wide applications in urogynecology, but the literature
supporting these modalities is still in its infancy, and costs
eﬀectiveness needs to be continuously assessed.
5.2. Recommendations: Level 2− Grade D. Although the
literature would suggest at least an equivalence of DRS to
other surgical approaches, due to the increased cost of DRS,
we will need further information from randomized trials
to better characterize the utility of DRS before adopting
it as routine use for sacrocolpopexies. Also, as mentioned
previously, long-term clinical outcomes are lacking. The
results of a randomized controlled trial just completed at the
Cleveland Clinic comparing DRS and LSC in sacrocolpopexy
will be instrumental in helping discern the utility of DRS in
urogynecology.
6.GynecologicOncology Surgery
6.1. Uterine Cancer. Uterine cancer is the most common
gynecologic cancer among women in the US, accounting
for 6% of all female cancers, and approximately 2.6% of
w o m e nw i l lb ea ﬀected by uterine cancer in their lifetime
[72]. The primary management of uterine cancer involves
a hysterectomy, bilateral salpingooophorectomy (BSO), and
when feasible pelvic and para-aortic lymphadenectomy to
better characterize the disease due to the risks of occult
spread. While the utility of lymphadenectomy and complete
staging during surgery is still debated, many gynecologic
oncologists use information from staging to help tailor
adjuvant therapies [73]. Since Childers ﬁrst demonstrated
the feasibilityof LSCinstaging uterine cancer,there hasbeen
an increase in the use of LSC in staging women with uterine
cancer [74]. This change has resulted in decreased morbidity
postoperatively. In fact, a recent randomized controlled trial
from the Gynecologic Oncology Group, the LAP2 trial, has
compared LSC to OS for surgical staging of uterine cancer
and found similar intraoperative complication rates, but
fewerpostoperative complications and shorter hospital stays,
with no diﬀerence in detection of advanced stage disease
[75]. They also showed a modest improvement in quality of
life [76]. Unfortunately, only 6-week postoperative outcomes
were assessed, so no conclusions regarding diﬀerences in
long-term outcomes can be made. However, they reported
a 26% conversion rate to OS among the patients randomized
to LSC, mostly due to poor visibility [75]. With the DRS, the
challenges of visibility with LSC can be overcome as well as
manyotherlimitationofLSC.Hence,theﬁeldofgynecologic
oncologyhasbegunadoptingtheDRSinperformingsurgical
stagingofuterinecancerduetoitsshorterlearningcurveand
ease of use. In fact, a recent survey of gynecologic oncologist
has found that nearly 40% of respondents felt that robotic
surgical training was required as a part of their career goals,
and 73% had performed a robotic hysterectomy [77]. Also,
at a large academic teaching hospital, after the introduction
of the DRS, the proportion of cases done minimally invasive
for uterine cancer staging increased from 6.4% prerobotics
to 80.5% in the third year after its introduction [7].
Many studies looking at DRS in uterine cancer staging
include case reports and case series. However, more recent
studies have begun to look at comparative observational data
of DRS versus OS and LSC in uterine cancer staging; in fact,
fourteen studies have been published to date. Unfortunately
two of these studies had sample sizes less than 20 and
were excluded [78, 79]. Of the twelve included, the size
of the robotic group ranged from 25 to 377, which, not
surprisingly, included the ﬁrst and the most recent study
reported to date and were from the same authors at the
Swedish Medical Center in Seattle, WA, USA (Table 2).
Also, among the selected studies that compared DRS to OS,
operative times were signiﬁcantly longer for DRS except
for one study with a nonsigniﬁcant diﬀerence [80], but
all studies showed a signiﬁcant improvement in blood loss
and duration of hospital stay among DRS compared to OS
(Table 2). The lymph node yields were also nonsigniﬁcantly
diﬀerent between DRS and OS, except for one study withObstetrics and Gynecology International 11
greater nodes in the DRS group [81]a n do n es t u d yw i t h
fewer nodes in the DRS group [82]. In regards to complica-
tions, DRS had either fewer intraoperative and postoperative
complications or no signiﬁcant diﬀerence compared to OS.
The important diﬀerence was that OS tended to have more
wound complications whereas DRS tended to have more cuﬀ
complications.
The diﬀerences between DRS and LSC are not as drastic
or consistent. For example, operative times were either
nonsigniﬁcantly diﬀerent or shorter for DRS compared to
LSC(Table2).However,onestudyreportedshorteroperative
times for LSC compared to DRS, and this was in a study
where only one surgeon performed all the procedures and
was very experienced with LSC [90]. Five studies reported
signiﬁcantly less blood loss with DRS compared to LSC,
whereas two studies showed no signiﬁcant diﬀerence. Half
the studies showed a decreased duration of hospital stay
with DRS compared to LSC, whereas the other half showed
no signiﬁcant diﬀerence. In regards to node yield, three
studies showed a beneﬁt with DRS, four studies showed
no diﬀerence, and one study showed a beneﬁt with LSC.
Complication rates were generally equivalent between DRS
and LSC, except for 2 studies that showed worse post-
operative complication rates with LSC, and one of these
demonstrated worse intraoperative complications for LSC as
well.However,inthatstudyallthecasesweredonebyasingle
surgeon who had just ﬁnished fellowship and all the LSC
complications occurred within his ﬁrst 40 cases [82].
Due to the observational nature of these studies, and
the aforementioned studies in general and reproductive
gynecology, many are fraught with potential biases including
selectionbias,investigatorbias,recallbias,andmanyrandom
eﬀects due to the uncontrolled nature of the studies. For
example, many of the studies report some diﬀerences in
demographics between the comparison groups. Also, the
data collection methods (e.g., retrospective and prospective)
were often diﬀerent for the groups due to the use of
HCs, which can cause time period eﬀects. For example,
traditional practice 5 to 10 years ago likely kept patient in the
hospital longer after surgery compared to current practice.
Also, studies including diﬀerent surgeons with undoubtedly
diﬀerent skills and experience will change outcomes between
the groups. Even when subjects are matched by surgeon
or a study includes only one surgeon, outcomes can be
very diﬀerent across studies. Also, the surgeons performing
the procedures within and between studies are most likely
at diﬀerent time points in their learning curve causing
additional variability in outcome data. Thus, outcomes are
better assessed in the context of the studies’ methodology,
rather than as a composite score.
The ﬁrst study, by Veljovich et al. published a hetero-
geneous study of their ﬁrst 113 robotic cases and identiﬁed
25 that were done for uterine cancer staging and included
hysterectomy and lymph-node dissection which was com-
pared to 131 historic and concurrent controls of OS for
uterine cancer staging [83]. They found longer operative
times in DRS but shorter hospital stays and less EBL with
comparable node yields. There was a trend towards higher
major complications in OS (21% versus 8%). There were 9
wound complications in the OS group compared to none in
the DRS group. There was one case of a cuﬀ dehiscence that
required reoperation in the DRS group, and none in the OS
group. There was one reported conversion to OS secondary
to a BMI over 49. They also compared DRS to 4 cases
of LSC, which had equivalent short-term and perioperative
outcomes, but, due to small case numbers, no conclusions
c a nb em a d e[ 83].
Boggess et al. then published their report of 103 DRS
for uterine cancer staging compared to 81 LSC-staging and
138 OS-staging procedures [81]. They found that although
patientsintheDRSgrouphadahigheraverageBMI,EBLwas
less, hospital stay was shorter, and node yield was higher as
compared to OS and LSC. Also, postoperative complications
were signiﬁcantly less among the DRS group compared to
the OS group. However, complication rates and conversion
rates for LSC and DRS were equivalent. They concluded
that DRS was superior to OS for uterine cancer staging and
may even be preferable over LSC. From the same institution,
Gehrig et al. published a similar study looking at a subset
of women with BMI over 30 who were undergoing DRS
or LSC for uterine cancer staging [84]. In this subset of
women, DRS was associated with signiﬁcantly less operative
times, EBL, and hospital stay, as well as increased node
y i e l d .C o m p l i c a t i o nr a t e sw e r ee q u i v a l e n ta n dt h e r ew a so n e
conversion to OS from LSC in a morbidly obese woman.
Their results suggest that DRS is superior to LSC for obese
and morbidly obese women undergoing surgical staging of
uterine cancer.
Bell et al. in 2008 published another study comparing
all three modalities (DRS, OS, and LSC) for uterine cancer
staging, but in a private practice with all the cases being done
bythesamesurgeon[86].Theyalsoperformedacostanalysis
of the three modalities using the outcomes they reported.
From a total of 110 cases, they found that DRS had longer
operative times compared to OS, but operative times were
equivalent to LSC. DRS, however, had less EBL than OS, and
fewer complications than both OS and LSC. Hospital stay
was shorter for DRS compared to OS, but not diﬀerent from
LSC. When evaluating the time to return to normal activity,
DRS was signiﬁcantly less than OS and LSC (24 versus 52
versus 32 days, resp.). Additionally, there was no diﬀerence
in node yield between the three modalities. In their costs
analysis, they assessed costs rather than hospital charges,
which,astheymentioned,isamoreaccuratereﬂectionofthe
ﬁnancial impact of the modalities on the health care system.
After accounting for costs of hospitalizations, the direct and
indirectcostsofOSwereonaverageover$4500.00morethan
DRS. However, DRS was on average $642.00 more expensive
than LSC. They concluded that although DRS uterine cancer
staging was longer, it was preferable over OS and LSC [86].
DeNardis et al. then looked at 56 patients that were
scheduled to undergo DRS for uterine cancer staging by
several diﬀerent surgeons during the ﬁrst 14 months of
starting their DRS at the Florida Hospital Cancer Institute
[87]. They were compared to 106 consecutive patients
that underwent OS immediately before starting their DRS
program. However, patients that had DRS were younger,
thinner, and tended to have less cardiopulmonary disease.12 Obstetrics and Gynecology International
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Still, they found that DRS had longer operative times,
but less EBL, blood transfusions, duration of hospital stay,
with no diﬀerence in node yield. Also, major perioperative
c o m p l i c a t i o n sw e r el e s sw i t hD R Sv e r s u sO S( 3 . 6 %v e r s u s
20.8%). They reported a conversion rate of 5.4% due to one
case of minor bleeding associated with poor visualization
and the other case was secondary to a posterior ﬁbroid
obliterating the cul-de-sac.
Seamon et al. at Ohio University compared 105 DRS
cases performed by two experienced laparoscopic surgeons
to those surgeons’ previous LSC cases in the 7 years prior
[88]. Although patients in the DRS group had higher BMI,
they still had improved EBL, duration of hospital stay, and
equivalent node yield, but, as expected, higher operative
times compared to LSC. They also noted fewer blood trans-
fusions with DRS, but complication rates were otherwise
equal. Conversion rates were also less for DRS versus LSC
(12% versus 26%). The same group, in combination with the
University of Alabama, looked at 109 DRS cases compared
to 191 OS cases for women with uterine cancer undergoing
staging procedures with a BMI of 30 or greater [89]. Cases
were matched by BMI and surgeon, but the DRS patients
were still younger with fewer prior abdominal surgeries;
however, they had more comorbid illnesses. Also, the ﬁnal
analyses were as treated (e.g., not including DRS cases that
were converted to OS). Ninety-two of the 109 (86%) DRS
cases were completed with DRS and compared to their 162
matched OS cases. They found longer operative times for
D R Sv e r s u sO S ,b u ta se x p e c t e di m p r o v e dE B L ,d u r a t i o no f
hospital stay, blood transfusion rate, complication rates, and
wound complications. Yet, there was no diﬀerence in node
yield.
Jung et al. in Korea looked at 28 cases of DRS, 25 cases
of LSC, and 56 cases of OS for uterine cancer staging, all
datacollectionwasprospective,andtwosurgeonsperformed
all the cases [80]. Unlike the techniques described in the
majority of US studies, they only used 3 robotic arms and
theyperformedaLSCtuballigationpriortoplacementofthe
RUMI uterine manipulator. Also, their patient population
was much thinner with an average BMI of approximately
24. However, the groups were equally balanced across all
demographic variables and uterine size. They reported
longer hospital stays in the OS group and increased blood
transfusions and complication rates as compared to both
DRS and LSC. However, there were no diﬀerences in
operative times. Node yield was less in LSC compared
to DRS, but equivalent between DRS and OS. They also
reported no conversions to OS in the DRS or LSC groups.
Cardenas-Goicoechea et al. at the University of Penn-
sylvania compared 102 DRS cases and 173 LSC cases of
uterine cancer staging by a single experienced laparoscopic
surgeon [90]. Data was collected retrospectively, and the
LSC cases were done in the 4 years prior to the DRS cases.
Both groups were similar across demographics and uterine
size. Interestingly, they found longer operative times in the
DRS group, but less blood loss compared to LSC. There
was otherwise no diﬀerence in length of stay, node yield,
and rates of intraoperative and postoperative complications.
However, they noted lower rates of ureteral complications
with DRS due to the improved visualization allowing for
easier identiﬁcation and manipulation of the ureters.
Lim et al. at the Center of Hope in Reno, Nevada
evaluated the outcomes between the three diﬀerent surgical
approaches at the onset of learning among a single surgeon
in a solo practice [91]. His ﬁrst 56 DRS cases were compared
to his initial cases of LSC (n = 56) and OS (n = 36)
cases for uterine cancer staging. Patients in the DRS group
were thinner, but otherwise the groups were well balanced.
They found that DRS cases on average took longer than OS,
but were faster than LSC. Blood loss and hospital stay was
improved in the DRS group compared to both OS and LSC.
However, node yield was signiﬁcantly higher in OS and LSC
compared to DRS. Although there were more conversions
to OS among LSC cases, this number was not signiﬁcantly
diﬀerent. However, there were signiﬁcantly more intraop-
erative complications among LSC cases. This correlation is
likely due to the steep learning curve of LSC. In fact, the
learning curve for DRS began to decrease in slope after to
20th case and then plateaued, whereas for LSC the operative
times continued to decline even after the 40th case and
never reached a plateau in this study. The same group then
published their continued experience with DRS compared to
only LSC, which included 122 DRS cases and 122 LSC cases
(including cases reported in the previous study) [82]. These
groups were similar across age and BMI. Using a regression
model, they determined that the learning curve was reached
afterthe24thDRScaseandthe49thLSCcase.However, they
noted that learning curve for LSC, even after the 49th case,
continued to appear steep and did not plateau. Similar to
their prior study, DRS took longer, resulted in smaller node
yields, but had less blood loss, shorter hospital stays, and
fewer intraoperative complications. However, the increased
conversion rates to OS from LSC are signiﬁcantly higher as
well as the postoperative complication rates compared to
DRS.
T h em o s tr e c e n ta n dl a r g e s ts t u d yt od a t ew a sp u b l i s h e d
by Paley et al. at the Swedish Medical Center [7]. They
prospectively reviewed their ﬁrst 1,000 DRS cases, 377 of
which were undergoing DRS for uterine cancer staging.
They compared these 377 cases to 131 HCs undergoing
OS for uterine cancer staging. Diﬀerent surgeons at the
same institution were performing the surgeries, and patient
demographics were comparable between the groups. Similar
to prior studies, DRS versus OS resulted in shorter hospital
staysandlessbloodloss.Also,intheiranalyses,theybrokeup
operativetimesbetweenthreetimeperiods(ﬁrstyear,second
year, and third year of experience) and found that operative
time signiﬁcantly decreased across these time cohorts, even
while average BMI increased. The most recent cohort has
averaged 207 minutes for completion of staging procedures
thatincludedpelvicandpara-aorticlymphadenectomy.Also,
the total complication rates were lower among DRS versus
OS(6.4%versus20.6%)andtheyhadaconversionratetoOS
of 3.5%, due to adhesive disease (4), inability to deliver the
uterus (4), and unanticipated extrauterine spread requiring
laparotomy for debulking (3).Obstetrics and Gynecology International 21
6.1.1. Recommendations: Level 2++ Grade C. These studies
suggest that DRS is preferable over OS for uterine cancer
staging because of the decrease in blood loss, hospital stay,
recovery time, and complication rate. DRS may be preferable
over LSC for uterine cancer staging among women with
a high probability of needing to convert to OS, such as
obese women, women with larger uteri, or women with
prior abdominal surgeries. DRS also may be preferable over
LSC for surgeons with less LSC experience. Despite the
aforementioned studies that support DRS, until long-term
outcomes are evaluated, such as tumor recurrence rates,
we cannot assume equivalence of the surgical modalities in
regards to their oncologic outcomes. Furthermore, in the US
wherehealthcareexpenditureisrisingwithlimitedresources,
we must consider costs as well. Barnett et al. have ently
reported that LSC is more cost eﬀective from both a societal
and hospital perspective [100]. While DRS may be preferred
and even advantageous over LSC and OS, we must proceed
with caution before adopting DRS as common practice.
6.2. Cervical Cancer. Another common application of DRS
in gynecologic oncology since its introduction has been
in the surgical management of early stage cervical cancer.
Worldwide cervical cancer is the second most common can-
ceramong women. Fortunately in the US the rates of cervical
cancer have declined signiﬁcantly over the last 50 years due
to the advent and adoption of routine pap smears. However,
many women are still aﬀected by cervical cancer in the US
with approximately 493,000 new cases and 274,000 deaths
reportedin2002[∗∗∗].Formanydecades,womenwithearly
cervical cancer have been managed with abdominal radical
hysterectomies with excellent cure rates. However, with the
introduction of laparoscopy, many gynecologic oncologists
have begun utilizing LSC to perform radical hysterectomies.
Several studies have shown decreased blood loss, hospital
stay, recovery times, and increased cosmesis and quality
of life by performing LSC radical hysterectomies (LRHs)
compared to traditional abdominal radical hysterectomies
(ARHs) [36, 101, 102]. However, similar to LSC for uterine
cancer staging, LSC for radical hysterectomies can be tech-
nically challenging for surgeons not experienced with LSC.
Radical hysterectomies are technically challenging even in
an open setting due to the extensive ureterolysis required
and dissection around the bladder and rectum in order to
resect the parametrium and uterosacral ligaments with the
uterus and cervix. Hence, DRS oﬀers better control and
visualization over LSC during this complex procedure. The
ﬁrst reported case of robotic radical hysterectomies (RRH)
was by March et al. who reported 30 gynecologic cases using
DRS, 7 of which were type II radical hysterectomies for
stage I cervical cancer [50]. Subsequently Sert and Albert
published a case report of a type III radical hysterectomy
[103] followed by a comparative case series of their ﬁrst 7
RRHs compared to 8 LRHs. They reported no diﬀerence in
operative times or node yield and size of parametrial tissue
excised, but bleeding and hospital stays were shorter for
RRH[104].Thesestudieswerefollowedbyseveraladditional
case series [105–108]. Here we will focus on comparative
studies meeting the aforementioned inclusion and exclusion
criteria. For a more complete and comprehensive review of
theliterature,seetherecentreportof“RoleofRobot-Assisted
Surgery in Cervical Cancer,” by Yim et al. [109].
Soon after Sert and Albert published their comparative
data on RRH [104], Magrina et al. at the Mayo Clinic in
Arizona published their experience with RRH compared to
A R Ha n dL R H[ 92]. The 27 RRH cases included 18 done
f o rc e r v i c a lc a n c e ra n d9d o n ef o re n d o m e t r i a lc a n c e r .T h e y
matched these cases to ARH and LRH cases with similar age,
BMI, malignancy, stage, and type of radical hysterectomy.
They found longer operative times for LRH compared to
RRH, but RRH and ARH were equivalent. Blood loss was
less for RRH compared to ARH, but RRH and LRH were
not signiﬁcantly diﬀerent. Also, complication rates and node
yield were equivalent across all modalities, and there were no
conversions to OS. Furthermore, with an average followup of
31 months, none of the 18 patients with cervical cancer had
recurred.Thus,theyconcludedthatroboticandlaparoscopic
procedures were preferable over open surgery for radical
hysterectomies [92].
Boggess et al. then published their outcomes of their
ﬁrst 51 consecutive cases of type III RRH compared to 49
cases of type III ARH for early cervical cancer done prior to
initiation of the robotics program [85]. These patients were
matched based on cancer type and stage. The groups were
comparable in BMI and uterine size, but the RRH group
was signiﬁcantly younger and more likely to have had prior
abdominal surgery (51% versus 18%). Still, the RRH group
had signiﬁcantly shorter operative times, less blood loss,
shorter hospital stays, and higher node yields than the ARH
group. Lastly, complication rates were equivalent. Again, this
study suggests the superiority of RRH over ARH.
The next two comparative studies included 12 and 16
patients in the RRH groups and thus were excluded from
this review, but nonetheless concluded that RRH was likely
advantageous over ARH from their case-control outcome
data [110, 111]. Geisler et al. then published their experience
with their ﬁrst 30 cases of type III RRH compared to
30 previous cases of type III ARH [93]. Patients were
comparable in age and BMI. They found decreased blood
loss and length of hospital stay among the RRH group, but
increased cases of urinary retention among RRH compared
to ARH. However, operative time, node yield, and size of
parametrial tissue were equivalent. They also found higher
rates of urinary retention up to 1 month after surgery in the
RRH group, but by 90 days there was no diﬀerence.
Estape et al. at South Miami Hospital published their
experience with 32 RRH cases compared to 17 and 14
stage and tumor-type matched cases of LRH and ARH [94].
The same surgeon performed all the LRH and ARH cases,
and two surgeons performed all the RRH cases. Patients
were comparable, except that patients in the RRH were
signiﬁcantly older than ARH patients. Still, RRH was faster
andhadimprovedbloodloss,durationofhospitalstays,time
toreturntowork,withhighernodeyieldscomparedtoARH.
Also, RRH was equivalent to ARH in regards to surgical
margin status and complication rates, but there was a trend
towards decreased complications among RRH compared to
ARH (19% versus 29%). RRH also appeared equivalent to22 Obstetrics and Gynecology International
LRH in regards to operative times, blood loss, and hospital
stay, but resulted in higher node yields. And again, there
was no signiﬁcant diﬀerence in complication rates, but a
trend towards decreased complications with RRH compared
toLRH(19%versus24%).Theyalsolookedatsurvivalstatus
among the three groups, and there were no diﬀerences, but
due to drastic diﬀerences in follow-up times, it is diﬃcult to
make any conclusions from their survival rates. They con-
cluded that RRH was superior to both ARH and LRH [94].
Whereas the aforementioned studies all suggest a beneﬁt
of RRH over ARH, LRH appears equivalent or inferior
to RRH in regards to operative times, node yield, or
complication rates. However, Nezhat et al. published a
comparative case series of type III RRH to LRH and
found equivalent outcomes in regards to operative time,
blood loss, hospital stay, complication rates, and node yield
between the two modalities [112]. Experienced laparoscopic
surgeons performed all of the procedures, and the groups
were comparable in regards to demographics and tumor
characteristics. They also reported no recurrences in a mean
follow-up time of 12 months and 29 months in the RRH
and LRH groups. However, due to their small sample size
(n = 17 in the RRH group) there is a high probability of a
type II error, that is, LRH is indeed inferior to RRH, but such
ad i ﬀerence was not detectable. Due to the small sample size
thisstudywasexcludedfromthetabulatedsystematicreview.
Althoughtheirﬁndingssuggestanequivalenceofroboticand
laparoscopy,theauthorsrefrainfrommakingthatconclusion
and astutely note:
...our evidence, as well as the evidence of
others, supports robotic surgery as a more
attractive option, both for the surgeon and
the patient. However, questions remain, includ-
ing whether the robot provides any additional
beneﬁts to a surgeon who is an experienced
laparoscopist and comfortable performing the
most advanced gynecologic procedures using
traditional laparoscopy, whether there is an
advantage for an inexperienced laparoscopic
surgeon to use robotic technology compared
with traditional laparoscopic instrumentation,
and what the learning curve is with either
approach [112].
The only other study that exclusively compared RRH to
LRH has been recently published by Tinelli et al. [98] They
compared 23 RRH to 76 LRH done at their center in Italy or
MountSinaiinNewYorkforearlystagecervicalcancer.They
excluded women with a BMI >35. Again, the groups were
comparable. The only signiﬁcant diﬀerence was a decreased
operative time for RRH compared to LRH, otherwise all
the outcomes were similar; and disease-free survival was
96% and 94% for the RRH and LRH patients respectively,
a nonsigniﬁcant diﬀerence. Again, RRH appears equivalent
to LRH in experienced hands but may still have advantages
in decreasing operative times and complications.
Another study by Lambaudie et al. evaluated the use of
OS, LSC, and DRS in managing locally advanced cervical
cancer after chemoradiation [113]. Although the types of
procedures done in each group are not clearly deﬁned
(lymph-nodedissectionsversussimplehysterectomiesversus
radical hysterectomies), they found that DRS reduced hos-
pital stays and had a lower rate of serious complications as
compared to OS. However, like Nezhat et al., they found no
diﬀerence in outcomes between DRS and LSC [112]. They
thus concluded that, “despite the multiple advantages of
robotic assistance published in the literature, robot-assisted
procedures have no advantages compared to traditional
laparoscopic radical hysterectomy when performed by an
experience laparoscopic surgeon” [113].
The only other study published to date that compares
RRH to LRH is by Sert and Albert from Norway [97].
However, this comparative case series includes only 7 cases
of LRH. Unlike Nezhat et al. [112] and Tinelli et al. [98],
they found that LRH had longer operative times, hospital
stays, and higher blood loss compared to RRH. Although the
groups were comparable, due to their small sample size, it is
hard to draw any conclusions.
Sert and Albert also compared RRH to ARH, again
the groups were comparable, and like the previous studies
RRH was advantageous due to shorter operative times,
hospital stays and decreased blood loss. However, they found
that RRH resulted in signiﬁcantly fewer pelvic lymph-node
yields compared to ARH. They did not comment on the
diﬀerence in complication rates, but it appears that the RRH
had signiﬁcantly fewer postoperative complications (11%
versus 46%). They did report long-term clinical outcomes
such as cervical cancer recurrences, and despite balanced
tumor characteristics between the groups and shorter mean
followup times in the RRH group (36 months) compared
to both the LRH (56 months) and the ARH (70 months)
groups, all the recurrences (5) were in the RRH group and
none in the LRH or ARH group. Although the size of the
parametrial tissue and vaginal edge were equivalent between
groups, the striking diﬀerence in recurrence rates questions
the adequacy of RRH in resecting disease [97]. However,
with small sample sizes, this diﬀerence in recurrence rates is
unlikely to be signiﬁcant. More studies need to be done to
assess long-term oncologic outcomes among these patients
managed with diﬀerent surgical modalities.
The last three studies identiﬁed are all case-control
comparative analyses of RRH compared to ARH; however,
one of these studies had a sample size of 14 and thus was
excluded from the systematic review [114]. This study from
the Netherlands nonetheless had comparable groups and
found signiﬁcantly less blood loss and shorter hospital stays
among the RRH group with no diﬀerence in node yields. It
took 9 hours to complete their ﬁrst RRH case, but after only
14 cases the operative time was reduced to just 4 hours. This
was similar to the 3 hours and 45 minutes average among
their open cases. Again, followup times were shorter for the
RRH group compared to the historic control ARH group, yet
therewere2recurrencesintheRRHgroupof14patients,and
1 in the ARH group of 13 patients. One of these recurrences
included a pelvic-side wall recurrence concurrent with a port
site metastasis that was managed with resection and pelvic
radiation. Maggioni et al. then published their experience
in Italy with RRH compared to ARH [95]. The groupsObstetrics and Gynecology International 23
were comparable across demographics, comorbidities, and
stage; however, patients in the RRH group were on average
signiﬁcantly younger (44 versus 50 years old). Like most
previous studies, they found longer operative times for RRH,
but less blood loss and shorter hospital stays. However,
they found signiﬁcantly fewer node yields and no signiﬁcant
diﬀerence in postoperative complication rates. They also
noted no diﬀerence in bladder dysfunction postoperatively.
Their long-term followup, although shorter for the RRH
group, revealed an equivalent number of recurrences in
both groups (5) with equal numbers of local and distant
recurrences. One distant recurrence in the RRH group
involved a port-site. They concluded that RRH is feasible
and safe, but hesitated to say it was superior without further
cost-beneﬁt analyses and assessment of long-term oncologic
outcomes.
Lastly, Nam et al. from Korea compared 32 cases of
RRH to 32 historic matched cases of ARH [96]. Unlike
previousstudiesweredemographicswere“comparable,”here
the patient demographics and tumor characteristics were
almost identical due to matching. Also, the RRH cases were
collected after one year of initiating the robotics program,
hence eliminated eﬀects from the early parts of the learning
curve. They found no diﬀerence in operative times or
complications, but RRH had decreased blood loss and length
of hospital stay. Their long-term followup, which was less in
the RRH group, revealed two recurrences in the RRH group
versus none in the ARH group. Therefore, they state that
RRH seems to be preferable over ARH, but they encourage
that more long-term oncologic outcome data is taken and
prospective randomized trials are completed before robotic
surgery becomes routine in managing patients with cervical
cancer. A phase 3 protocol comparing LRH or RRH to ARH
has been published and completion of this trial and their
results are anxiously awaited [115].
In addition to radical hysterectomies, the DRS has been
utilized in several other procedures when managing cervical
cancer. Radical trachelectomies with lymphadenectomy are
an option for women with early stage (IA-IB1) cervical
cancer who desire fertility preservation. Although several
case reports [108, 116–118] and two case series [119, 120]
are encouraging in regards to the feasibility and safety of
DRSinperformingradicaltrachelectomies,thesamplesizeis
limitedtoatotalof14casesbetweenallthestudies,andlong-
term clinical outcomes such as recurrence rates and fertility
ratesarelacking.Inadditiontotrachelectomies,DRShasalso
been described in performing radical parametrectomies in 5
patients [121] and a description of the surgical technique of
DRS in uterine artery sparing radical trachelectomies [122],
lymph-node dissections [123, 124], nerve-sparing radical
hysterectomies [99], and even pelvic exenterations [125–
127]. However, once again, these studies are either descrip-
tions of techniques, case reports, or small case series with
no comparative data. These studies suggest that DRS may be
feasible in performing the aforementioned procedures, but
further studies are needed before such surgical management
approaches can be considered acceptable.
6.2.1. Recommendations: Level 2++ Grade C. These studies,
like those in uterine cancer staging, suggests that RRH is
preferable over ARH due to its decrease in blood loss,
hospital stay, recovery time, and complications. However,
RRH appears to be equivalent to LRH in the hands of
experienced surgeons. Again, if a patient is predicted to
have a high chance for conversion to OS from LSC, even
an experienced LSC surgeon may prefer DRS to prevent
conversion and decrease complications. In addition, a less
experienced LSC may prefer RRH to LRH. Once again,
before the adoption of RRH into common practice for the
management of early cervical cancer, further cost-eﬀective
analyses, evaluation of long-term oncologic outcomes, and
theanticipatedresultsfromthephaseIIIrandomizedcontrol
trial need to be critically assessed.
6.3. Ovarian Cancer. One in 72 women will develop epithe-
lial ovarian cancer (EOC) over the course of their lifetime,
and unfortunately, there is a dismal 5-year survival rate
of only 46% [128]. EOC is staged surgically which for
almost a century has involved an exploratory laparotomy
with hysterectomy, adnexectomy, abdominal-pelvic wash-
ings, peritoneal biopsies, omentectomy, pelvic and para-
aortic lymphadenectomy, and debulking of metastatic tumor
when feasible with a goal of leaving no residual disease. For
85% of ovarian cancer patients with advanced stage disease
these surgeries often require extensive dissections within the
pelvis and upper abdomen and can require bowel surgery or
at minimum mobilization of the bowel to adequately explore
the pelvis and abdomen. Minimally invasive surgery can be
very challenging in many of these cases. However, among
the 15% of ovarian cancer patients with early stage disease
conﬁned to one or both ovaries or with extension to pelvic
structures only, the utilization of LSC and DRS is now being
considered. Unfortunately, this body of literature is still in
its infancy including a couple case reports and case series
[49, 111, 129] and one comparative case-control study [130].
A recent review article has reviewed these case reports and
case series in addition to all the literature evaluating the use
of MIS in staging EOC and borderline ovarian tumors [131].
They concluded:
There still are only limited data with regard to
minimally invasive surgery for ovarian cancer;
however, in the setting of [borderline ovarian
tumors] BOTs and presumed early-stage EOC,
minimally invasive surgical staging performed
by a trained gynecologic oncologist appears to
be safe and eﬀective when compared to laparo-
tomy. The minimally invasive approach allows
for equivalent staging adequacy with fewer
intraoperativecomplicationsandashorterpost-
operative recovery [131].
Subsequent to this review, Magrina et al. compared 25
cases of DRS utilized for staging of EOC compared to
27 LSC cases and 119 OS cases done during the same
period or in the 3 years prior matched by age, BMI, type
and number of procedures done [130]. They also broke
each cohort into subset by type of debulking. Type I
included primary tumor excision including hysterectomy,24 Obstetrics and Gynecology International
adnexectomy, omentectomy, pelvic and para-aortic lym-
phadenectomy, appendectomy and the removal of peritoneal
disease if present. Type II included the aforementioned
procedures and one additional major procedure, while type
III had an additional 2 or more major procedures. The
majority of patients studied had advanced (stage III-IV)
EOC: 60%, 75%, and 87% in the DRS, LSC, and OS
groups, respectively. Although they do not mention if these
diﬀerences in proportion are signiﬁcantly diﬀerent, they
could bias the results of the study in favor or DRS and even
LSC. This diﬀerence in stage may also aﬀect the optimal (no
visibledisease)debulkingratesreportedbetweenthecohorts:
84%, 93%, and 56% in the DRS, LSC, and OS groups,
respectively. Also, approximately 25% of the patients in
all the groups received neoadjuvant chemotherapy, making
determination of surgical stage impossible among this subset
of patients. Hence, there is potential for several biases due
to the heterogeneity of patients within and between cohorts.
Nonetheless, they did ﬁnd decreased blood loss and hospital
stay among DRS and LSC patients compared to OS patients,
but there was no diﬀerence between DRS and LSC. Also,
operative times were longer for DRS, but LSC and OS were
similar. The only diﬀerence in perioperative outcomes was
a signiﬁcantly decreased post-operative complication rate
among DRS and LSC patients that had type II debulkings.
There was no signiﬁcant diﬀerence among those having type
I debulking surgeries, and among those getting type III, only
2patientshadDRS,andtheremaining32hadOS.Therefore,
the numbers are too small for comparison. They did report
long-term outcome data, both 3-year overall survival (OS)
and 3-year progression-free survival (PFS) between the three
surgical modalities and within subsets based on early and
late stage disease. There was no diﬀerence in OS in early and
late stage EOC and no diﬀerence in PFS in early stage EOC
between all three surgical modalities. However, there was a
signiﬁcantly diﬀerent 3-year PFS among DRS, LSC, and OS
at 56%, 49%, and 30%, respectively (P = 0.03). Although
P<0.05, due to the multiple log-rank tests done with
no adjustment for multiplicity, this is likely a type I error.
Based on their ﬁndings they conclude that DRS and LSC are
preferable over OS for patients requiring a type II ovarian
debulking procedure and that survival was unaﬀected by
surgical approach (see Table 3).
6.3.1. Recommendations: Level 2− Grade D. The prior study
suggests at least equivalence of DRS and LSC compared to
OS for EOC debulking with one or no additional major
procedures, but due to the many potential confounding
variables, no conclusions or ﬁnal recommendations can be
given from this single study. Also, there is not enough data to
support the feasibility and safety of DRS in debulking EOC
in cases that require at least 2 additional major procedures.
Furthermore, there is not enough data to support the
equivalency in terms of progression free survival or overall
survivalanditisdoubtfulthataminimallyinvasiveapproach
wouldoﬀeranequalopportunityforasurgeontoperforman
optimal cytoreduction whencomparedto an open approach.
Therefore it is not advised to perform robotic-assisted
surgery for the diagnosis and management of advanced
(stage III-IV) ovarian cancer outside of study protocol.
7. Conclusions
Robotic surgery oﬀers many new advantages in the ﬁeld
of gynecology. Among general and reproductive gynecology
as well as urogynecology, surgeries that would have tradi-
tionally been done as an exploratory laparotomy may now
be done robotically, thus, avoiding the morbidity associated
with an open surgery. In the ﬁeld of gynecologic oncology,
surgeries that have traditionally been done with exploratory
laparotomy, are now being done with the DRS. Nonetheless,
many of these procedures in benign and oncologic gyne-
cology, may be completed with conventional laparoscopy as
well in the hands of an experienced laparoscopic surgeon.
However, even with an experienced and skilled surgeon,
obese patients, patients with prior abdominal surgeries,
or patients requiring lengthy and high-risk surgeries likely
beneﬁt from DRS over LSC. Thus, each case must be
considered individually with careful attention to the disease,
the patient and their comorbidities and goals, the skill and
conﬁdence of the surgeon, and the practice setting. For
example, DRS may be more feasible and cost eﬀective in a
hospital equipped with a routinely used DRS that also has
well-trained staﬀ that can assist and troubleshoot the device
as needed.
However, as mentioned previously, many of the disease
states for which DRS is being used have limited long-
term outcome data, which is very important in regards
to oncologic outcomes and urogynecologic outcomes. Also,
all the outcomes discussed are from comparative observa-
tional studies, with a variety of methodologies and patient
characteristics. Thus, the results cannot be generalized to
all patients, but rather must be considered in the context
in which the studies were done and applied to individual
scenarios only when appropriate. Until larger, well-designed
observational studies or randomized control trials are com-
pleted which also report long-term outcomes, we cannot
deﬁnitively state the superiority of DRS over other surgical
methods; although, the majority studies do suggest DRS is
preferred over OS and possibly LSC.
With any new innovation comes great potential for
progress, but also harm. This notion applies to DRS. With
therightamountoftrainingandskill,alongwithappropriate
patient selection, DRS can be highly advantageous. Patients
will likely have less blood loss, less post-operative pain, faster
recoveries, and fewer complications compared to OS and
potentially even LSC. Yet, in agreement with the ACOG
Technology Assessment of “Robot-Assisted Surgery” in 2009
[132], further studies as well as additional cost-eﬀective
analyses need to be done to critically evaluate the role
of robotic surgery in gynecology before it is adopted as
common practice in managing gynecologic diseases.
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